Literature DB >> 18486921

Rheumatic disorders as paraneoplastic syndromes.

Vito Racanelli1, Marcella Prete, Carla Minoia, Elvira Favoino, Federico Perosa.   

Abstract

The long-established observation that some rheumatologic disorders (RDs) are associated with--or precede--the clinical manifestations of a variety of solid and hematological tumors represents an important clue for the early diagnosis and effective treatment of the cancers. Inflammatory myopathies, seronegative rheumatoid arthritis and some atypical vasculitides are the most frequently reported paraneoplastic RDs, although paraneoplastic scleroderma- and lupus-like syndromes, erythema nodosum, and Raynaud's syndrome have also been observed. Generally, the clinical course of a paraneoplastic RD parallels that of the cancer, and surgical removal of the tumor or its medical treatment usually results in a marked regression of the clinical manifestations of the RD. Most paraneoplastic RDs are difficultly distinguishable from idiopathic RDs. Even so, some atypical features of the clinical presentation raise the suspicion of an underlying tumor. This review summarizes current hypotheses for the pathogenesis that leads a tumor to present as an RD and discusses the clinical features that help distinguish paraneoplastic from idiopathic RDs.

Entities:  

Mesh:

Year:  2008        PMID: 18486921     DOI: 10.1016/j.autrev.2008.02.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  48 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

2.  A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: investigating mechanisms of pathogenesis.

Authors:  G Freimanis; P Hooley; H Davari Ejtehadi; H A Ali; A Veitch; P B Rylance; A Alawi; J Axford; A Nevill; P G Murray; P N Nelson
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

3.  Angioimmunoblastic T-Cell Lymphoma with Polyarthritis Resembling Rheumatoid Arthritis.

Authors:  Ralph Yachoui; Nouman Farooq; Jonathan V Amos; Gene R Shaw
Journal:  Clin Med Res       Date:  2016-12

4.  Association between rheumatic diseases and cancer: results from a clinical practice cohort study.

Authors:  Mattia Bellan; Enrico Boggio; Daniele Sola; Antonello Gibbin; Alessandro Gualerzi; Serena Favretto; Giulia Guaschino; Ramona Bonometti; Roberta Pedrazzoli; Mario Pirisi; Pier Paolo Sainaghi
Journal:  Intern Emerg Med       Date:  2017-02-08       Impact factor: 3.397

5.  The age-risk relationship of hematologic malignancies in patients with rheumatoid arthritis: a nationwide retrospective cohort study.

Authors:  Yu-Chih Lin; Hui-Wen Chou; Wen-Chan Tsai; Jeng-Hsien Yen; Shun-Jen Chang; Yi-Ching Lin
Journal:  Clin Rheumatol       Date:  2015-05-20       Impact factor: 2.980

6.  Recurrent metastatic breast cancer presenting with paraneoplastic scleroderma.

Authors:  Timothy David Reynolds; Sally Elizabeth Knights
Journal:  BMJ Case Rep       Date:  2014-03-11

Review 7.  The lung cancer nurse role in the management of paraneoplastic syndromes in lung cancer.

Authors:  John White
Journal:  Transl Lung Cancer Res       Date:  2016-06

Review 8.  Report of anti-CCP antibody positive paraneoplastic polyarthritis and review of the literature.

Authors:  Emily Larson; Delene Etwaru; Chokkalingam Siva; Kenneth Lawlor
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

9.  The presenting manifestations of subcutaneous panniculitis-like T-cell lymphoma and T-cell lymphoma and cutaneous γδ T-cell lymphoma may mimic those of rheumatic diseases: a report of 11 cases.

Authors:  Lin Yi; Shi Qun; Zheng Wenjie; Zhang Wen; Li Jian; Zhao Yan; Zhang Fengchun
Journal:  Clin Rheumatol       Date:  2013-04-16       Impact factor: 2.980

10.  Paraneoplastic Raynaud's phenomenon in a breast cancer survivor.

Authors:  David Allen; David Robinson; Shikha Mittoo
Journal:  Rheumatol Int       Date:  2009-06-11       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.